Oxidative, Reductive, and Hydrolytic Metabolism of Drugs

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 15-35

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular location reaction stoichiometry; Enzymes and drug metabolism; Polyunsaturated fatty acids epoxide derivatives

Indexed keywords

EID: 84889459943     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch2     Document Type: Chapter

References (67)

1. Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. A genetic polymorphism of the N-oxidation of trimethylamine in humans. Clin Pharmacol Therap 1987;42:588-594.
2. Baker MT, Van Dyke RA. Reductive halothane metabolite formation and halothane binding in rat hepatic microsomes. Chem-Biol Interact 1984;49:121-132.
3. Burk RF. Selenium-dependent glutathione peroxidases. In: Guengerich FP, editor. Biotransformation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 229-242.
4. Burka LT, Guengerich FP, Willard RJ, Macdonald TL. Mechanism of cytochrome P-450 catalysis. Mechanism of N-dealkylation and amine oxide deoxygenation. J Am Chem Soc 1985;107:2549-2551.
5. Cashman JR. Monoamine oxidase and flavin-containing monooxygenases. In:Guengerich FP, editor. Biotransformation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 69-96.
6. Chandrasena RE, Vatsis KP, Coon MJ, Hollenberg PF, Newcomb M. Hydroxylation by the hydroperoxy-iron species in cytochrome P450 enzymes. J Am Chem Soc 2004;126:115-126.
7. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N Jr. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 1985;13:342-347.
8. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol 2002;53:408-409.
9. Deng Y, Wang Z, Gu S, Ji C, Ying K, Xie Y, Mao Y. Cloning and characterization of a novel human alcohol dehydrogenase gene (ADHFel). DNA Seq 2002;13:301-306.
10. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985;260:9057-9067.
11. Duester G, Jarrks J, Felder MR, Holmes RS, Hoijg J-O, Paris X, Plapp BV, Yin S-J, Jornvall H. Recommended nomenclature for the vetebrate alchol dehydrogenase gene family. Biochem Pharmacol 1999;58:389-395.
12. Edenberg HJ, Bosron WF. Alcohol dehydrogenases. In: Guengerich FP, editor. Biotransformation, Vol. 3, Comprehesive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 119-131.
13. Ellis EM, Judah DJ, Neal GE, Hayes JD. An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc Natl Acad Sci USA 1993;90:10350-10354.
14. Flynn TG, Kubiseski TJ. Aldo-keto reductases: structure, mechanism, and function. In: Guengerich FP, editor. Biotransformation, Vol. 3, Comprehensive Toxicology. first ed. Elsevier Science, Oxford; 1997. p 133-147.
15. Frederick CB, Mays JB, Ziegler DM, Guengerich FP, Kadlubar FF. Cytochrome P450 and flavin-containing monooxygenase-catalyzed formation of the carcinogen Nhydroxy-2-aminofluorene, and its covalent binding to nuclear DNA. Cancer Res 1982;42:2671-2677.
16. Gonzalez-Duarte R, Albalat R. Merging protein, gene and genomic data: the evolution of the MDR-ADH family. Heredity 2005;95:184-197.
17. Gozukara EM, Belvedere G, Robinson RC, Deutsch J, Coon MJ, Guengerich FP, Gelboin HV. The effect of epoxide hydratase on benzo[a]pyrene diol epoxide hydrolysis and binding to DNA and mixed-function oxidase proteins. Mol Pharmacol 1981;19:153-161.
18. Guengerich FP. Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 1987;262:8459-8462.
19. Guengerich FP. Biotransformation, Vol. 3, Compr Toxicology, first ed. Elsevier Science, Oxford; 1997.
20. Guengerich FP. Human cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
21. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001;14:611-650.
22. Guengerich FP. Cytochrome P450 oxidations in the generation of reactive electrophiles:epoxidations and related reactions. Arch Biochem Biophys 2003;409:59-71.
23. Guengerich FP. Human cytochrome P450 enzymes, In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, Mechanism, and Biochemistry, third ed. Kluwer Academic/Plenum Publishers; New York: 2005. p 377-531.
24. Guengerich FP, Macdonald TL. Chemical mechanisms of catalysis by cytochromes P-450: a unified view. Acc Chem Res 1984;17:9-16.
25. Guengerich FP, Cai H, McMahon M, Hayes JD, Sutter TR, Groopman JD, Deng Z, Harris TM. Reduction of aflatoxin B, dialdehyde by rat and human aldo-keto reductases. Chem Res Toxicol 2001;14:727-737.
26. Guengerich FP,Wu Z-L, Bartleson CJ. Function of human cytochrome P450s: characterization of the remaining orphans. Biochem Biophys Res Commun 2005;338:465-469.
27. Hammock BD, Grant DF, Storms DH. Epoxide hydrolases. In: Guengerich FP, editor. Biotransforrnation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 283-305.
28. Hayashi Y, Yamazaki I. The oxidation-reduction potentials of compound I/compound II and compound II/ferric couples of horseradish peroxidases A2 and C. J Biol Chem 1979;254:9101-9106.
29. Huang M-T, Miwa GT, Cronheim N, Lu AYH. Rat liver cytosolic azoreductase. Electron transport properties and the mechanism of dicoumarol inhibition of the purified enzyme. J Biol Chem 1979;254:11223-11227.
30. Jaiswal AK. Human NAD(P)H-quinone oxidoredutase. Gene structure, activity, and tissue-specific expression. J Biol Chem 1994;269:14502-14508.
31. Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997;54:639-647.
32. Johnson WW, Ueng Y-F, Yamazaki H, Shimada T, Guengerich FP. Role of microsomal epoxide hydrolase in the hydrolysis of aflatoxin B1 8,9-epoxide. Chem Res Toxicol 1997;10:672-676.
33. Josephy PD, Guengerich FP, Miners JO. Phase 1 and phase 2 drug metabolism:terminology that we should phase out. Drug Metab Dispos 2005;37:579-584.
34. Kalgutkar AS, Gardner I, Obach RS, Shjaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Jee JS, Nakai Y, O'Donnell JP, Boer, Harriman SP. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225.
35. Ketterer B, Meyer DJ. Glutathione transferases: a possible role in the detoxication and repair of DNA and lipid hydroperoxides. Mut Res 1989;214:33-40.
36. Kim D, Kadlubar FF, Teitel CH, Guengerich FP. Formation and reduction of aryl and heterocyclic nitroso compounds and significance in the flux of hydroxylamines. Chem Res Toxicol 2004;17:529-536.
37. Kurosaki M, Terao M, Barzago MM, Bastone A, Bemardinello D, Salmona M, Garattini E. The aldehyde oxidase gene cluster in mice and rat. Aldehyde oxidase homologue 3, a novel member of the molybdo-flavoenzyme family with selective expression in the olfactory mucosa. J Biol Chem 2004;279:50482-50498.
38. Lacourciere GM, Armstrong RN. The catalytic mechanism of microsomal epoxide hydrolase involves an ester intermediate. J Am Chem Soc 1993;115:10466-10467.
39. Lacourciere GM, Armstrong RN. Microsomal and soluble epoxide hydrolases are members of the same family of C-X bond hydrolase enzymes. Chem Res Toxicol 1994;7:121-124.
40. Macdonald TL, Gutheim WG, Martin RB, Guengerich FP. Oxidation of substituted N,N-dimethylanilines by cytochrome P450: estimation of the effective oxidation-reduction potential of cytochrome P450. Biochemistry 1989;28:2071-2077.
41. Marnett LJ, Landino LM, Reddy GR. Peroxidases. In: Guengerich FP, editor. Biotransformation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 149-163.
42. Massey V. The chemical and biological versatility of riboflavin. Biochem Soc Trans 2000;28:283-296.
43. Miyamoto G, Zahid N, Uetrecht JP. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol 1997;10:414-419.
44. Miyate M, Kudo G, Lee Y-H, Y.mg TJ, Gelboin HV, Fernandez-Salguero, Kimura S, Gonzalez FJ. Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic acitvity of 7,12-dimethylbenz[a]anthracene. J Biol Chem 1999;274:23963-23968.
45. Nicholls CD, Shields MA, Lee PWK, Robbins SM, Beattie TL. UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation. J Biol Chem 2004;279:24171-24178.
46. Ortiz de Montellano PR, De Voss JJ. Substrate oxidation by cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, Mechanism, and Biochemistry, third ed. Kluwer Academic/Plenum Publishers; New York: 2005. p 183-245.
47. Panoutsopoulos GI, Kouretas D, Beedham C. Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes. Chem Res Toxicol 2004;17:1368-1376.
48. Penning TM. Introduction and overview of the aldo-keto reductase superfamily. In:Penning TM, Petrash JM, editors. Aldo-Keto Reductases and Toxicant Metabolism. first ed. Washington, DC: American Chemical Society; 2004. p 3-20.
49. Petersen D, Lindahl R. Aldehyde dehydrogenases. In: Guengerich FP, (editor). Biotransformation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 97-118.
50. Quinn DM. Esterases of the a,b hydrolase fold family. In: Guengerich FP, editor. Biotransformation, Vol. 3, Comprehensive Toxicology. first ed. Elsevier Science, Oxford; 1997. p 243-264.
51. Rajagopalan KV. Xanthine dehydrogenase and aldehyde oxidase. In: Guengerich FP, (editor). Biotransformation, Vol. 3, Comprehensive Toxicology. first ed. Elsevier Science, Oxford; 1997. p 165-178.
52. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448.
53. Ross D. Quinone reductases. In: Guengerich FP, (editor). Biotransformation, Vol. 3, Comprehensive Toxicology, first ed. Elsevier Science, Oxford; 1997. p 179-197.
54. Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet BM, Ringe D, Petsko GA, Sligar SG. The catalytic pathway of cytochrome P450cam, at atomic resolution. Science 2000;287:1615-1622.
55. Seto Y, Guengerich FP. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J Biol Chem 1993;268:9986-9997.
56. Shaik S, Kumar D, de Visser SP, Altun A, Thiel W. Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. Chem Rev 2005;105:2279-2328.
57. Sinal CJ, Miyate M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000;275:40504-40510.
58. Sone T, Wang CY. Microsomal amidases and caraboxylesterases. In: Guengerich FP, (editor). Biotransformation, Vol. 3, Comprehensive Toxicology. first ed. Elsevier Science, Oxford; 1997. p 265-281.
59. Takimoto K, Lindahl R, Pitot HC. Regulation of 2,3,7,8-tetrachlorodibenzo-p-dioxininducible expression of aldehyde dehydrogenase in hepatoma cells. Arch Biochem Biophys 1992;298:492-497.
60. Tzeng H-F, Laughlin LT, Lin S, Armstrong RN. The catalytic mechanism of microsomal epoxide hydrolase involves reversible formation and rate-limiting hydrolysis of the alkyl-enzyme intermediate. J Am Chem Soc 1996;118:9436-9437.
61. Van Houten KA, Kim JM, Bogdan MA, Feni DC, Mariano PS. A new strategy for the design of monoamine oxidase inactivators. Exploratory studies with tertiary allylic and propargylic amino alcohols. J Am Chem Soc 1998;120:5864-5872.
62. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomic 2005;2:138-143.
63. Williams JA, Hyland R, Jones BC, Smith DA, Hust S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-1208.
64. Wislocki PG, Miwa GT, Lu AYH. Reactions catalyzed by the cytochrome P-450 system. In: Jakoby WB, (editor). Enzymatic Basis of Detoxication, Vol. I. first ed. New York: Academic Press; 1980. p 135-182.
65. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. CRC Crit Rev Toxicol 1992;22:1-21.
66. Ziegler DM. Recent studies on the structure and function of multisubstrate flavincontaining monooxygenases. Annu Rev Pharmacol Toxicol 1993;33:179-199.
67. Ziegler DM, Mitchell CH. Microsomal oxidase IV: properties of a mixed-function amine oxidase isolated from pig liver microsomes. Arch Biochem Biophys 1972; 150:116-125.